NCT04556461View on ClinicalTrials.gov

Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

July 1, 2022

Study Completion Date

March 31, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

Tralokinumab

2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)

Trial Locations (1)

24105

UKSH, Campus Kiel, Kiel

All Listed Sponsors
lead

Prof. Dr. Stephan Weidinger

OTHER

NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function | Biotech Hunter | Biotech Hunter